Metropolitan Life Insurance Company (MetLife)’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-3,921
| Closed | -$267K | – | 2396 |
|
|
2022
Q3 | $267K | Hold |
3,921
| – | – | 0.01% | 586 |
|
|
2022
Q2 | $125K | Hold |
3,921
| – | – | 0.01% | 930 |
|
|
2022
Q1 | $136K | Sell |
3,921
-12,697
| -76% | -$380K | ﹤0.01% | 1012 |
|
|
2021
Q4 | $486K | Hold |
16,618
| – | – | 0.01% | 1451 |
|
|
2021
Q3 | $423K | Hold |
16,618
| – | – | 0.01% | 1572 |
|
|
2021
Q2 | $582K | Buy |
16,618
+12,305
| +285% | +$480K | 0.01% | 1421 |
|
|
2021
Q1 | $176K | Sell |
4,313
-195
| -4% | -$8.96K | ﹤0.01% | 2112 |
|
|
2020
Q4 | $195K | Sell |
4,508
-24
| -0.5% | -$1.18K | ﹤0.01% | 1955 |
|
|
2020
Q3 | $250K | Sell |
4,532
-117
| -3% | -$7.44K | ﹤0.01% | 1646 |
|
|
2020
Q2 | $293K | Sell |
4,649
-12,990
| -74% | -$891K | 0.01% | 1559 |
|
|
2020
Q1 | $901K | Buy |
17,639
+215
| +1% | +$14.4K | 0.02% | 733 |
|
|
2019
Q4 | $1.39M | Sell |
17,424
-539
| -3% | -$31.9K | 0.02% | 730 |
|
|
2019
Q3 | $872K | Buy |
17,963
+807
| +5% | +$42.1K | 0.01% | 931 |
|
|
2019
Q2 | $902K | Buy |
17,156
+283
| +2% | +$16.3K | 0.02% | 953 |
|
|
2019
Q1 | $893K | Buy |
16,873
+562
| +3% | +$27.6K | 0.02% | 945 |
|
|
2018
Q4 | $670K | Hold |
16,311
| – | – | 0.01% | 1027 |
|
|
2018
Q3 | $620K | Hold |
16,311
| – | – | 0.01% | 1219 |
|
|
2018
Q2 | $737K | Buy |
16,311
+4,030
| +33% | +$183K | 0.01% | 1082 |
|
|
2018
Q1 | $593K | Buy |
12,281
+215
| +2% | +$12K | 0.01% | 1167 |
|
|
2017
Q4 | $475K | Sell |
12,066
-13,426
| -53% | -$501K | 0.01% | 1322 |
|
|
2017
Q3 | $792K | Hold |
25,492
| – | – | 0.01% | 1391 |
|
|
2017
Q2 | $697K | Buy |
25,492
+13,957
| +121% | +$415K | ﹤0.01% | 1460 |
|
|
2017
Q1 | $425K | Hold |
11,535
| – | – | ﹤0.01% | 1760 |
|
|
2016
Q4 | $167K | Hold |
11,535
| – | – | ﹤0.01% | 2458 |
|
|
2016
Q3 | $266K | Hold |
11,535
| – | – | ﹤0.01% | 2148 |
|
|
2016
Q2 | $191K | Buy |
+11,535
| New | +$233K | ﹤0.01% | 2346 |
|
|
2016
Q1 | – | Sell |
-7,158
| Closed | -$231K | – | 2537 |
|
|
2015
Q4 | $231K | Buy |
+7,158
| New | +$310K | ﹤0.01% | 2155 |
|
Other funds holding GBT
Metropolitan Life Insurance Company (MetLife)'s GBT Position: Q4 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 3,921 shares — an estimated $267K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in GBT in Q4 2015 and held it in 27 quarters. The position peaked at $1.39M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 3,921 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $267K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 27 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Global Blood Therapeutics, Inc. position peaked at $1.39M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2022, filed 15 Feb 2023.